Picture of Immunocore Holdings logo

IMCR — Immunocore Holdings News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedMid CapSucker Stock

Immunocore Holdings PLC expected to post a loss of 32 pence a share - Earnings Preview

* Immunocore Holdings PLC  IMCR.OQ   IMCR.O  is expected
to show a
rise in quarterly revenue when it reports  results on August
10. 
    * The Abingdon Oxfordshire-based  company is expected to
report  a
45.2% increase in revenue to £46.456 million from £32 million a
year ago, according to the mean estimate from 11 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Immunocore Holdings
PLC
is for a loss of 32 pence per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Immunocore
Holdings PLC is $80​, above​ its last closing price of $62.34.
​​​

Previous quarterly performance (using preferred earnings measure
in pounds). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.36       -0.32      -0.35     Missed  -7.7
 Dec. 31 2023  -0.01       0.00       -0.54     Missed  -2,523
                                                        ,264.5
 Sep. 30 2022  -0.22       -0.29      0.12      Beat    141.7​
 Jun. 30 2022  -0.59       -0.67      -0.14     Beat    79.1
 ​​Mar.        -0.82       -0.84      -0.37     Beat    56.2
 31 2022                                                
 Dec. 31 2021  -0.80       -0.82      -0.91     Missed  -10.9​
 Sep. 30 2021  -0.75       -0.63      -0.68     Missed  -8.1
 Jun. 30 2021  -0.69       -0.68      -0.74     Missed  -7.8
 This summary was machine generated August 8 at 14:21 GMT.  All
figures in pounds  unless otherwise stated

Recent news on Immunocore Holdings

See all news